A 13-valent pneumococcal conjugate vaccine (PCV13) has been developed to improve protection against pneumococcal disease beyond that possible with the licensed 7-valent vaccine (PCV7). This study compared the safety and immunogenicity of PCV13 with those of PCV7 when given as part of the pediatric vaccination schedule recommended in Italy. A total of 606 subjects were randomly assigned to receive either PCV13 or PCV7 at 3, 5, and 11 months of age; all subjects concomitantly received diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B (DTaP-HBV-IPV/Hib) vaccine. Vaccine reactions were monitored. Antibody responses to DTaP-HBV-IPV/Hib antigens, serotype-specific anticapsular polysaccharide IgG responses, and antipneumococcal opsonophagocytic assay (OPA) activity were measured 1 month after the two-dose primary series and 1 month after the toddler dose. Overall, the safety profile of PCV13 was similar to that of PCV7. The response to DTaP-HBV-IPV/Hib antigens was substantially the same with both PCV13 and PCV7. PCV13 elicited antipneumococcal capsular IgG antibodies to all 13 vaccine serotypes, with notable increases in concentrations seen after the toddler dose. Despite a lower immunogenicity for serotypes 6B and 23F after the primary series of PCV13, responses to the seven common serotypes were comparable between the PCV13 and PCV7 groups when measured after the toddler dose. PCV13 also elicited substantial levels of OPA activity against all 13 serotypes following both the infant series and the toddler dose. In conclusion, PCV13 appeared comparable to PCV7 in safety profile and immunogenicity for common serotypes, demonstrated functional OPA responses for all 13 serotypes, and did not interfere with immune responses to concomitantly administered DTaP-HBV-IPV/Hib vaccine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2884425 | PMC |
| http://dx.doi.org/10.1128/CVI.00062-10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages.
Methods: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%.
Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine is Reduced in Infants Immunized during the Respiratory Viral Season.
Clin Infect Dis
December 2024
Ben Gurion University, Faculty of Health Sciences, The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Beer Sheva, Israel.
Introduction: We hypothesized that response to infant pneumococcal conjugate vaccines (PCVs), administered during peak respiratory viral seasons could be blunted, particularly to higher carrier-load PCVs.
Methods: We did a post-hoc analysis of a large, double-blind, randomized study comparing 13-valent vs. 7-valent PCVs (PCV13; PCV7) administered to infants (at 2, 4, 6, and 12 months).
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US.
Vaccines (Basel)
November 2024
Pfizer Inc., 2909 LD Capelle aan den Ijssel, The Netherlands.
(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first year of life at 2, 4, and 6 months, while a booster dose is given at 12 to 15 months. This study evaluated the health and economic effects of the PCV20 infant series within the first year of life compared to PCV15.
View Article and Find Full Text PDFInvasive Pneumococcal Diseases in People over 65 in Veneto Region Surveillance.
Vaccines (Basel)
October 2024
Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, 35128 Padua, Italy.
Background: Elderly individuals over 65, along with children under 5, are the most affected by invasive pneumococcal diseases (IPDs). Monitoring vaccination coverage and conducting surveillance are essential for guiding evidence-based prevention campaigns and public health measures.
Methods: Since 2007, the Veneto Region has relied on three sources for surveillance of invasive bacterial infections, contributing to an increase in reported IPD cases.
Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany.
Vaccines (Basel)
September 2024
Division of Pediatric Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
Article Synopsis
- This study evaluated the cost-effectiveness of the 20-valent pneumococcal conjugate vaccine (PCV20) compared to the 15-valent vaccine (PCV15/V114) for childhood immunization in Germany using a decision-analytic Markov model.
- The model assessed the lifetime costs and health outcomes by tracking pneumococcal infection incidences and complications while incorporating indirect effects like herd immunity.
- Although PCV20 showed a higher prevention rate of disease and greater quality-adjusted life years (QALYs) gained, it also incurred a significantly higher cost, raising concerns about its economic efficiency compared to V114.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!